Vertex Pharmaceuticals VRTX Current State And Local Tax Expense Benefit
Current State And Local Tax Expense Benefit at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CurrentStateAndLocalTaxExpenseBenefit.
The official record: Vertex Pharmaceuticals’s 10-K, filed February 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vertex Pharmaceuticals's current state and local tax expense benefit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vertex Pharmaceuticals's current state and local tax expense benefit?
- Vertex Pharmaceuticals (VRTX) reported current state and local tax expense benefit of $8.98M in Q4 2025.
- How has Vertex Pharmaceuticals's current state and local tax expense benefit changed year-over-year?
- Vertex Pharmaceuticals's current state and local tax expense benefit decreased by 69.6% year-over-year, from $29.55M to $8.98M.
- What is the long-term trend for Vertex Pharmaceuticals's current state and local tax expense benefit?
- Over 2 years (2023 to 2025), Vertex Pharmaceuticals's current state and local tax expense benefit has grown at a -11.8% compound annual growth rate (CAGR), from $46.2M to $35.9M.